InventisBio's Nomelcitinib Shows Promising Efficacy and Safety in Phase III Trial for Plaque Psoriasis

InventisBio Co., Ltd. announced positive topline results from a registrational Phase III clinical trial for its JH2 selective TYK2 inhibitor, nomelcitinib (D-2570), in treating moderate-to-severe plaque psoriasis. The study met both primary and key secondary endpoints, demonstrating clinically and statistically significant superiority over placebo. Nomelcitinib showed a rapid onset of action and a favorable safety profile consistent with earlier studies.